UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no gra...

Full description

Saved in:
Bibliographic Details
Main Authors: Petrioli, R, Sabatino, M, Fiaschi, A I, Marsili, S, Pozzessere, D, Messinese, S, Correale, P, Civitelli, S, Tanzini, G, Tani, F, De Martino, A, Marzocca, G, Lorenzi, M, Giorgi, G, Francini, G
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2004
Subjects:
Short Communication
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409570/
https://ncbi.nlm.nih.gov/pubmed/14735168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601521
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items